Group 1 - Celcuity (NASDAQ: CELC) recently announced positive results from its phase 3 VIKTORIA-1 trial, which tested its drug gedatolisib in combination with other therapies for treating patients with PIK3CA wildtype HR+/HER2- advanced breast cancer [2] - The trial involved a triplet therapy approach, indicating a potential advancement in treatment options for this specific type of breast cancer [2] Group 2 - The Biotech Analysis Central service offers in-depth analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] - The service is available for $49 per month, with a discounted yearly plan at $399, providing a 33.50% savings for subscribers [1]

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist healthcare investors [2] - The subscription for Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, reflecting a 33.50% discount [1][2] Group 2 - The article does not contain any stock, option, or similar derivative positions in the companies mentioned, nor does it plan to initiate any such positions within the next 72 hours [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that no specific investment recommendations are provided [4]

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist healthcare investors [2] Group 2 - The service is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] - The analyst has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3]

Group 1 - The article discusses Tiziana Life Sciences (NASDAQ: TLSA) and its ongoing drug development efforts, particularly focusing on the Foralumab drug and its additional Expanded Access Program (EAP) enrollment [2] - The author is affiliated with Biotech Analysis Central, which provides extensive analysis and resources for healthcare investors, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] - The service offered by Biotech Analysis Central is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] Group 2 - The article does not provide specific financial data or performance metrics related to Tiziana Life Sciences or its products [4] - There are no disclosed positions or plans to initiate positions in the companies mentioned, indicating a neutral stance from the author [3]

Core Insights - Capricor Therapeutics, Inc. (NASDAQ: CAPR) is set to have its Biologics License Application (BLA) for deramiocel, aimed at treating Duchenne Muscular Dystrophy (DMD), reviewed by the FDA with a Priority Review Prescription Drug User Fee Act (PDUFA) date approaching [2] Company Overview - Capricor Therapeutics focuses on developing innovative therapies for rare diseases, particularly in the field of muscular dystrophy [2] Market Context - The FDA's Priority Review designation indicates that the agency recognizes the potential significance of deramiocel in addressing unmet medical needs in DMD patients, which could lead to expedited review and approval processes [2]

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Biotech Analysis Central includes a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist healthcare investors [2] - The service is priced at $49 per month, with a yearly plan available at a discounted rate of $399, reflecting a 33.50% discount [1] Group 2 - The article does not provide any specific investment recommendations or advice regarding the suitability of investments for particular investors [4] - The author has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3] - The views expressed in the article may not represent those of Seeking Alpha as a whole, as the platform includes contributions from various authors, both professional and individual investors [4]

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Biotech Analysis Central provides a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist healthcare investors [2] Group 2 - The service is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% discount [1] - The analyst has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3]

Group 1 - Moderna (NASDAQ: MRNA) shares have decreased over 35% year-to-date and over 80% on a one-year basis, with a decline of 94% since reaching a pandemic-era high of over $450 per share [1] - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including catalysts to watch, buy and sell ratings, product sales forecasts, and integrated financial statements [2] Group 2 - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies in the biotech, healthcare, and pharma sectors [2]

Company Overview - Akero Therapeutics (NASDAQ: AKRO) is actively developing its FGF21 drug efruxifermin, aimed at treating patients with compensated cirrhosis due to MASH and pre-cirrhotic MASH patients [2]. Product Development - The development of efruxifermin is a key focus for Akero Therapeutics, indicating strong progress in addressing significant medical needs within the liver disease space [2].

Group 1 - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and offers a model portfolio of small and mid-cap stocks [1][2] - The service includes over 600 biotech investing articles and live chat features to assist healthcare investors in making informed decisions [2] - A promotional offer is available for new subscribers, including a two-week free trial and a discounted annual subscription price [1] Group 2 - The author of the article has no current stock or derivative positions in any mentioned companies and does not plan to initiate any within the next 72 hours [3] - The article expresses the author's personal opinions and is not compensated beyond the Seeking Alpha platform [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [4]